Effect of tamsulosin combined with transurethral plasmakinetic resection of prostate on quality of life and sexual function in patients with benign prostatic hyperplasia

Abstract

Objective To investigate the influence of transurethral plasmakinetic resection of prostate (TUPKRP) and oral tamsulosin on quality of life and sexual function in patients with benign prostatic hyperplasia (BPH).

Methods A total of 80 patients with BPH admitted to The Department of Urology of The Third People’s Hospital of Bengbu from June 2018 to January 2020 were selected and divided into treatment group ( n = 40) and control group ( n = 40) by random number table method. The treatment group was treated with TUPKRP combined with oral tamsulosin, while the control group was treated with TUPKRP only. Quality of life [International prostate quality of Life Score (QOL), International prostate symptom Score (IPSS), maximum urine flow rate (Qmax), residual urine volume (RUV), times of night urination], sexual function [International erectile function index (IIEF-5)] and incidence of complications were compared between 2 groups before and 6 months after treatment.

Results There were no significant differences in QOL, IPSS, Qmax, RUV and IIEF-5 between the two groups before treatment (all P > 0.05). Six months after treatment, IIEF-5 of the treatment group and the control group were (19.35 ± 4.16) points and (17.03 ± 3.52) points. QOL, IPSS, Qmax, RUV and IIEF-5 of the two groups were improved compared with that before treatment, IPSS, QOL, Qmax and IIEF-5 of the treatment group were better than that of the control group. Nocturia [(1.13 ± 0.88) times] in the treatment group was less than that in the control group [(1.65 ± 0.86) times], and the incidence of complications in the treatment group was less than that in the control group, with statistical significance (all P < 0.05).

Conclusion Tamsulosin combined with TUPKRP is beneficial to improve postoperative urination, quality of life and sexual function in patients with BPH, which is worthy of clinical application.

Abstract

摘要：目的 探讨经尿道前列腺等离子电切术 (transurethral plasmakinetic resection of prostate, TUPKRP)联合口服 坦索罗辛对前列腺增生患者生活质量及性功能的影响。 方法 选取2018年6月一2020年1月期间蚌埠市第三 人民医院泌尿外科收治的前列腺增生患者80例, 采用随机数字表法分成治疗组(40例)和对照组(40例)。治疗 组行TUPKRP联合口服坦索罗辛治疗, 对照组仅行TUPKRP治疗。比较2组治疗前、治疗后6个月生活质量[国 际前列腺生活质量评分(QOL)、国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、剩余尿量(RUV)、夜间排尿次 数)]、性功能[国际勃起功能指数(IIEF-5)]及并发症发生率。 结果 2 组治疗前QOL、IPSS、Qmax、RUV及IIEF-5 比较差异无统计学意义(均 P > 0.05);治疗后6个月, 治疗组和对照组IIEF-5为 (19.35 ± 4.16)分和 (17.03 ± 3.52)分, 2组QOL、IPSS、Qmax、RUV及IIEF-5均较治疗前改善, 治疗组IPSS、QOL、Qmax及IIEF-5评分优于对照 组;治疗组夜尿次数[(1.13 ±0.88)次]少于对照组[(1.65 ± 0.86)次], 治疗组并发症发生率低于对照组, 差异均 有统计学意义(均 P < 0.05)。 结论 坦索罗辛联合TUPKRP治疗前列腺增生患者有利于改善术后排尿、生活质 量及性功能, 值得临床推广应用。